Form 4: ELUTIA CSO Reports RSU Vesting & Tax Withholding

Elutia Inc.'s Chief Scientific Officer, Michelle LeRoux Williams, reported the vesting of 12,500 restricted stock units and the subsequent sale of 3,951 shares for tax obligations.

Summary

• Michelle LeRoux Williams, Chief Scientific Officer of Elutia Inc., reported changes in her beneficial ownership of the company's securities.
• On December 10, 2025, 12,500 shares of Class A Common Stock were acquired due to the vesting of restricted stock units (RSUs).
• Concurrently, 3,951 shares of Class A Common Stock were disposed of at a price of $0.7 per share to satisfy tax withholding requirements related to the RSU vesting.
• Following these transactions, Williams directly beneficially owns 101,934 shares of Class A Common Stock.
• She also directly beneficially owns 50,000 restricted stock units.
• The vesting is part of a pre-scheduled grant of 150,000 restricted stock units awarded on January 31, 2024, with a vesting schedule extending until December 10, 2026.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-scheduled insider transaction involving RSU vesting and tax-related share disposition. It reflects standard compensation practices and does not indicate any significant positive or negative operational or financial news, but rather a predictable event.

Positives

• The vesting of restricted stock units indicates the retention and incentivization of a key management personnel, aligning their interests with shareholders.
• The transaction is part of a pre-scheduled vesting plan, suggesting a predictable and transparent compensation structure.

Negatives

• The disposition of 3,951 shares, although for tax purposes, represents a reduction in direct beneficial ownership of common stock.
• The reported sale price of $0.7 per share for tax withholding purposes is notably low, which could be a point of concern depending on the prevailing market price of Elutia Inc. Class A Common Stock.

Future Outlook

The filing details a pre-established vesting schedule for restricted stock units extending quarterly until December 10, 2026, indicating a long-term incentive plan for the Chief Scientific Officer.

Industry Context

This is a routine insider transaction filing (Form 4) for a public company. Such filings are common and reflect standard equity compensation practices in industries that rely on attracting and retaining highly skilled executives, such as the biotechnology or pharmaceutical sector, where Elutia Inc. likely operates given the 'Chief Scientific Officer' role. The vesting and subsequent tax-related sale are typical events for executives receiving equity awards.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation is a common practice across various industries, including biotech and healthcare, aligning executive incentives with long-term company performance.
• The automatic sale of shares to cover tax obligations upon RSU vesting is a standard procedure, often facilitated by Rule 10b5-1 plans, which this filing indicates was made pursuant to such a plan.
• The specific vesting schedule (1/6 initially, then 1/12 quarterly) is a common structure designed to retain executives over several years, providing a staggered incentive.

Related Party Transactions

• The transaction involves the company and its Chief Scientific Officer, which is a related party. However, it represents a standard equity compensation event rather than an unusual related party dealing.

Stakeholder Impact

• Shareholders: The vesting and subsequent tax-related sale of shares by a key executive is a routine event. The increase in shares outstanding from vesting is minimal relative to total shares. The continued equity ownership by the CSO aligns her interests with shareholders.
• Employees: The equity compensation structure for a senior executive may reflect broader company compensation policies, potentially impacting employee morale and retention strategies.

Next Steps

• Future quarterly vesting events for the remaining 50,000 restricted stock units are scheduled until December 10, 2026, as per the original grant terms.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled insider transaction related to equity compensation. It does not contain new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The vesting of RSUs and subsequent sale for tax purposes are expected events for executives with equity awards. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a basis for a 'buy' or 'sell' decision.

Keywords

Elutia Inc., ELUT, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Ownership, Chief Scientific Officer, Michelle LeRoux Williams, Equity Compensation, Tax Withholding